Compare Sun Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PFIZER - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PFIZER SUN PHARMA/
PFIZER
 
P/E (TTM) x 22.3 36.1 61.9% View Chart
P/BV x 2.6 6.1 42.9% View Chart
Dividend Yield % 0.6 0.6 108.9%  

Financials

 SUN PHARMA   PFIZER
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
PFIZER
Mar-19
SUN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6793,840 17.7%   
Low Rs3752,080 18.0%   
Sales per share (Unadj.) Rs121.1455.0 26.6%  
Earnings per share (Unadj.) Rs13.493.8 14.3%  
Cash flow per share (Unadj.) Rs20.7109.4 18.9%  
Dividends per share (Unadj.) Rs2.7522.50 12.2%  
Dividend yield (eoy) %0.50.8 68.6%  
Book value per share (Unadj.) Rs172.6658.2 26.2%  
Shares outstanding (eoy) m2,399.2645.75 5,244.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.5 66.9%   
Avg P/E ratio x39.431.6 124.8%  
P/CF ratio (eoy) x25.527.1 94.2%  
Price / Book Value ratio x3.14.5 67.9%  
Dividend payout %20.624.0 85.7%   
Avg Mkt Cap Rs m1,264,650135,420 933.9%   
No. of employees `00017.52.6 665.2%   
Total wages/salary Rs m59,6713,238 1,842.6%   
Avg. sales/employee Rs Th16,608.17,911.4 209.9%   
Avg. wages/employee Rs Th3,409.61,230.9 277.0%   
Avg. net profit/employee Rs Th1,833.81,630.7 112.5%   
INCOME DATA
Net Sales Rs m290,65920,815 1,396.4%  
Other income Rs m10,2551,674 612.6%   
Total revenues Rs m300,91422,489 1,338.1%   
Gross profit Rs m63,0765,712 1,104.3%  
Depreciation Rs m17,533714 2,455.9%   
Interest Rs m5,55373 7,616.6%   
Profit before tax Rs m50,2466,599 761.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0092,309 260.3%   
Profit after tax Rs m32,0934,291 748.0%  
Gross profit margin %21.727.4 79.1%  
Effective tax rate %12.035.0 34.2%   
Net profit margin %11.020.6 53.6%  
BALANCE SHEET DATA
Current assets Rs m310,69227,167 1,143.6%   
Current liabilities Rs m173,3968,917 1,944.6%   
Net working cap to sales %47.287.7 53.9%  
Current ratio x1.83.0 58.8%  
Inventory Days Days9968 146.1%  
Debtors Days Days11230 370.6%  
Net fixed assets Rs m232,4778,862 2,623.3%   
Share capital Rs m2,399458 524.4%   
"Free" reserves Rs m411,69129,656 1,388.2%   
Net worth Rs m414,09130,113 1,375.1%   
Long term debt Rs m15,22625 60,904.4%   
Total assets Rs m646,93839,400 1,642.0%  
Interest coverage x10.091.5 11.0%   
Debt to equity ratio x00 4,429.1%  
Sales to assets ratio x0.40.5 85.0%   
Return on assets %5.811.1 52.5%  
Return on equity %7.814.2 54.4%  
Return on capital %10.222.1 45.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,025428 15,415.7%   
Fx outflow Rs m38,610786 4,909.7%   
Net fx Rs m27,415-358 -7,655.7%   
CASH FLOW
From Operations Rs m21,965978 2,245.6%  
From Investments Rs m-6,813351 -1,939.8%  
From Financial Activity Rs m-27,305-1,099 2,485.7%  
Net Cashflow Rs m-8,442231 -3,657.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.1 7.5 68.4%  
FIIs % 23.0 4.9 469.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.7 35.0%  
Shareholders   133,026 85,207 156.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 416 Points Lower; Banking and Energy Stocks Witness Huge Selling(Closing)

After hitting record highs in the morning trade today, India share markets gave up all the gains and ended near day's low with Nifty below 12,250 level.

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 20, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ALEMBIC LTD COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS